anastrozole has been researched along with Hot Flashes in 11 studies
Hot Flashes: A sudden, temporary sensation of heat predominantly experienced by some women during MENOPAUSE. (Random House Unabridged Dictionary, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 9.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole." | 9.17 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 6.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| "Purpose The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efficacy and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor (HR) -positive and node-positive early breast cancer (eBC)." | 5.24 | Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation ( Amadori, D; Burris, H; Comarella, L; De Boer, R; Dowsett, M; Ejlertsen, B; Gnant, M; Hart, L; Jonat, W; McIntyre, K; O'Shaughnessy, J; Poggio, S; Pritchard, KI; Salomon, H; Smith, I; Wamil, B; Yardley, D, 2017) |
| "27 randomly assigned 7,576 postmenopausal women with breast cancer to 5 years of anastrozole or exemestane." | 5.20 | Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. ( Budd, GT; Chapman, JA; Ellis, MJ; Goss, PE; Ingle, JN; Kundapur, J; Le Maitre, A; Liedke, PE; Ma, CX; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Stearns, V, 2015) |
| "In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole." | 5.17 | Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. ( Ansari, RH; Budd, GT; Chalchal, H; Chapman, JA; D'Souza, DP; Elliott, C; Ellis, MJ; Gelmon, KA; Goss, PE; Ingle, JN; Johnson, DB; Lang, I; Liedke, PE; Perez, EA; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW; Spadafora, S; Stearns, V; Tozer, R, 2013) |
| "The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer." | 4.84 | Safety of aromatase inhibitors in the adjuvant setting. ( Perez, EA, 2007) |
| "Although anastrozole (Anas) plays a key role in the management of endocrine sensitive post-menopausal (PM) breast cancer (BC), there is much variability in its efficacy and tolerability." | 3.85 | Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study. ( Abubakar, MB; Gan, SH, 2017) |
| "The subjects were 10 patients with breast cancer who were undergoing antiestrogen therapy with tamoxifen or anastrozole and who were suffering from hot flashes." | 3.79 | Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women. ( Bong, JG; Jeong, YJ; Kwon, HJ; Park, SH; Park, YS; Shin, IH, 2013) |
| "Women with hormone-receptor-positive tumours who reported vasomotor or joint symptoms at the first follow-up visit (3 months) in the ATAC trial, (which assessed tamoxifen or anastrozole for adjuvant treatment of postmenopausal breast cancer), were compared with women without these symptoms to see if there was a relation between these symptoms and subsequent recurrence." | 3.74 | Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. ( Cella, D; Cuzick, J; Fallowfield, L; Sestak, I, 2008) |
| "Endocrine treatments of breast cancer patients antagonize estrogen and may lead to consequences of estrogen deprivation including menopausal symptoms." | 2.71 | Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. ( Ameye, L; Carbonez, A; Christiaens, MR; Morales, L; Neven, P; Paridaens, R; Timmerman, D; Van Huffel, S; Van Limbergen, E; Vergote, I, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 7 (63.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abubakar, MB | 1 |
| Gan, SH | 1 |
| Kyvernitakis, I | 1 |
| Ziller, V | 1 |
| Hars, O | 1 |
| Bauer, M | 1 |
| Kalder, M | 1 |
| Hadji, P | 1 |
| Stearns, V | 2 |
| Chapman, JA | 2 |
| Ma, CX | 1 |
| Ellis, MJ | 2 |
| Ingle, JN | 2 |
| Pritchard, KI | 3 |
| Budd, GT | 2 |
| Rabaglio, M | 2 |
| Sledge, GW | 2 |
| Le Maitre, A | 1 |
| Kundapur, J | 1 |
| Liedke, PE | 2 |
| Shepherd, LE | 2 |
| Goss, PE | 2 |
| Smith, I | 1 |
| Yardley, D | 1 |
| Burris, H | 1 |
| De Boer, R | 1 |
| Amadori, D | 1 |
| McIntyre, K | 1 |
| Ejlertsen, B | 1 |
| Gnant, M | 1 |
| Jonat, W | 1 |
| Dowsett, M | 1 |
| Hart, L | 1 |
| Poggio, S | 1 |
| Comarella, L | 1 |
| Salomon, H | 1 |
| Wamil, B | 1 |
| O'Shaughnessy, J | 1 |
| Cuzick, J | 1 |
| Sestak, I | 1 |
| Cella, D | 1 |
| Fallowfield, L | 1 |
| Terhorst, L | 1 |
| Blair-Belansky, H | 1 |
| Moore, PJ | 1 |
| Bender, C | 1 |
| Ansari, RH | 1 |
| Johnson, DB | 1 |
| Tozer, R | 1 |
| D'Souza, DP | 1 |
| Chalchal, H | 1 |
| Spadafora, S | 1 |
| Perez, EA | 2 |
| Lang, I | 1 |
| Elliott, C | 1 |
| Gelmon, KA | 1 |
| Jeong, YJ | 1 |
| Park, YS | 1 |
| Kwon, HJ | 1 |
| Shin, IH | 1 |
| Bong, JG | 1 |
| Park, SH | 1 |
| Morales, L | 1 |
| Neven, P | 1 |
| Timmerman, D | 1 |
| Christiaens, MR | 1 |
| Vergote, I | 1 |
| Van Limbergen, E | 1 |
| Carbonez, A | 1 |
| Van Huffel, S | 1 |
| Ameye, L | 1 |
| Paridaens, R | 1 |
| Wengström, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Light Emitting Diode for the Treatment of Genitourinary Syndrome of Menopause Associated With Hormonal Therapy for Treating Breast Cancer: Randomized Controlled Clinical Trial[NCT03833726] | 77 participants (Actual) | Interventional | 2019-01-30 | Completed | |||
| A Randomized Phase III Trial Of Exemestane Versus Anastrozole In Postmenopausal Women With Receptor Positive Primary Breast Cancer[NCT00066573] | Phase 3 | 7,576 participants (Actual) | Interventional | 2003-06-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical fracture at any time, including hip, spine, wrist fractures and other bone fractures. (NCT00066573)
Timeframe: 8 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 358 |
| Anastrozole | 354 |
Time to distant disease-free survival (DDFS) is defined as the time from randomization to the time of documented distant recurrence. Distant recurrence is the cancer coming back in a part of the body away from the breast, such as the bones or liver. (NCT00066573)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Exemestane | 157 |
| Anastrozole | 164 |
Event free survival, the primary endpoint of this study, is defined as the time from randomization to the time of documented locoregional or distant recurrence, new primary breast cancer, or death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Exemestane | 88 |
| Anastrozole | 89 |
Overall survival is defined as the time from randomization to the time of death from any cause. (NCT00066573)
Timeframe: 5 years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Exemestane | 92 |
| Anastrozole | 92 |
2 reviews available for anastrozole and Hot Flashes
| Article | Year |
|---|---|
Safety of aromatase inhibitors in the adjuvant setting.
Topics: Anastrozole; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast | 2007 |
Effectively nursing patients receiving aromatase inhibitor therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromat | 2008 |
5 trials available for anastrozole and Hot Flashes
| Article | Year |
|---|---|
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Anxiety; Aromatase Inhibitors; Breast Neoplasms; | 2014 |
Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial.
Topics: Adult; Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bre | 2015 |
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Breast Neoplasms; Chemotherapy, Adju | 2017 |
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Fe | 2013 |
Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
Topics: Anastrozole; Aromatase Inhibitors; Belgium; Body Mass Index; Breast Neoplasms; Data Interpretation, | 2004 |
4 other studies available for anastrozole and Hot Flashes
| Article | Year |
|---|---|
Correlation of Serum Estradiol and Duration of Anastrazole Therapy with Treatment Related Adverse Effects Among Postmenopausal Breast Cancer Women: A Cross-sectional Study.
Topics: Aged; Anastrozole; Breast Neoplasms; Cross-Sectional Studies; Estradiol; Female; Hot Flashes; Humans | 2017 |
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Arthralgia; Biomarkers, Tumor; Breast Neo | 2008 |
Evaluation of the psychometric properties of the BCPT Symptom Checklist with a sample of breast cancer patients before and after adjuvant therapy.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Checklist; Chemotherapy, Adjuv | 2011 |
Acupuncture for the treatment of hot flashes in patients with breast cancer receiving antiestrogen therapy: a pilot study in Korean women.
Topics: Acupuncture Therapy; Analysis of Variance; Anastrozole; Breast Neoplasms; Estrogen Antagonists; Fema | 2013 |